Bolt Biotherapeutics, Inc.
Net SellingBOLT·US·🇺🇸 US
34%buys·66%sales
575 transactions$106.2MTotal buys·61 buys
$2.4MTotal sells·121 sells
3030 insiders
Last: Dec 12, 2025
| Date | Insider | Type | Value | |
|---|---|---|---|---|
| Dec 12, 25 | Quinn William P. | Disposition | - | |
| Dec 12, 25 | Quinn William P. | Grant | - | |
| Dec 12, 25 | Quinn William P. | Disposition | - | |
| Dec 12, 25 | Quinn William P. | Grant | - | |
| Dec 12, 25 | Quinn William P. | Disposition | - | |
| Dec 12, 25 | Quinn William P. | Grant | - | |
| Dec 12, 25 | Quinn William P. | Disposition | - | |
| Dec 12, 25 | Quinn William P. | Grant | - | |
| Dec 12, 25 | Quinn William P. | Disposition | - | |
| Dec 12, 25 | Quinn William P. | Grant | - |
Bolt Biotherapeutics, Inc. (BOLT) has recorded 575 insider transactions from 30 insiders. Total insider buying volume stands at $106.2M, while total selling volume is $2.4M. Overall insider sentiment is bearish (66% sales).
Bolt Biotherapeutics, Inc. (BOLT) has recorded 575 insider operations, including 61 open-market purchases ($106.2M), 121 sales ($2.4M) and 393 other operations (stock option exercises, grants, tax dispositions, donations). The insider sentiment is bearish (66% sales).
Bolt Biotherapeutics, Inc. shows moderate insider activity with 5 active months out of the last 12, typical of a company whose trading windows are concentrated around financial disclosures.
Among the most active insiders are Schatzman Randall C (CEO), Quinn William P. (CEO) & Yonehiro Grant (C SUITE), with respectively 70, 41, 49 transactions.
Across all 575 recorded transactions, the breakdown by type is: exercise (203, 35%), grant (132, 23%), sales (121, 21%), buys (61, 11%), disposition (58, 10%).
Data sourced from regulatory filings (SEC Form 4, AMF, BaFin, FI, and other European authorities).
Bolt Biotherapeutics, Inc. has recorded 575 insider operations in total, including 61 open-market purchases ($106.2M), 121 sales ($2.4M) and 393 other operations (stock option exercises, grants, tax dispositions, donations). The most recent transaction was recorded on December 12, 2025.
Insiders at Bolt Biotherapeutics, Inc. are currently net sellers, with 34% purchases and 66% sales across all reported transactions. Total buy volume is $106.2M versus $2.4M in sales, indicating a bearish insider sentiment.
InsiderLens tracks 30 insiders at Bolt Biotherapeutics, Inc. (BOLT). Schatzman Randall C (CEO, 70 tx), Quinn William P. (CEO, 41 tx), Yonehiro Grant (C SUITE, 49 tx). Data is sourced from mandatory regulatory filings for persons with access to privileged information.
The insider signal for BOLT is bearish, based on a 34% buy ratio across 182 buy and sell transactions reported to financial regulators. Transactions from C-suite executives (CEO, CFO) and board members are generally considered the most informative signals.
Insider trading data for Bolt Biotherapeutics, Inc. comes from official regulatory filings: SEC Form 4 (United States), AMF (France), BaFin (Germany), FI (Sweden), and other European financial authorities. These filings are mandatory for directors, officers, and holders of more than 10% of a company's shares. InsiderLens aggregates and normalizes this data for analysis.